Spyre Therapeutics, Inc. SYRE Gain (Loss) on Derivative Instruments, Net, Pretax

Gain (Loss) on Derivative Instruments, Net, Pretax at other companies

SM EnergySM

-$697M-4,000%

Cipher Digital, Inc. CIFR

-$112.61M—

EnerSysENS

-$521K-138%

Hut 8 Mining Corp.HUT

$69K—

Restaurant Brands InternationalQSR

$41M-19.6%

MetLifeMET

$74M-82.9%

Other financials

Income statement

See full

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

See full

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

See full

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

See full

Market cap$7.67B+307%

Profitability

See full

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

See full

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDerivativeInstrumentsNetPretax.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s gain (loss) on derivative instruments, net, pretax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s gain (loss) on derivative instruments, net, pretax?: Spyre Therapeutics, Inc. (SYRE) reported gain (loss) on derivative instruments, net, pretax of -$30.27M in Q1 2026.
How has Spyre Therapeutics, Inc.'s gain (loss) on derivative instruments, net, pretax changed year-over-year?: Spyre Therapeutics, Inc.'s gain (loss) on derivative instruments, net, pretax decreased by 1361.3% year-over-year, from $2.4M to -$30.27M.